Skip to content

Application of Granzyme B-Targeted PET Probe in Evaluating Immunotherapy Efficacy in Malignant Tumor Patients

Application of Granzyme B-Targeted PET Probe in Evaluating Immunotherapy Efficacy in Malignant Tumor Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105792
Enrollment
Unknown
Registered
2025-07-10
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor

Interventions

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed malignant tumor; (2) At least one measurable lesion present; (3) Scheduled to receive immunotherapy (either as monotherapy or in combination with chemotherapy); (4) No prior history of immunotherapy; (5) No gender restrictions, aged 18 to 75 years (inclusive).

Exclusion criteria

Exclusion criteria: (1) Patients unsuitable for immunotherapy; (2) Patients unable or unwilling to provide written informed consent; (3) Patients with mobility impairments or those unable to lie flat for 30 minutes during examination; (4) Patients who are planning pregnancy, currently pregnant, or breastfeeding; (5) Patients with claustrophobia; (6) Severe liver or renal failure.

Design outcomes

Primary

MeasureTime frame
SUVmax;SUVmean;Sensitivity;Specificity;Accuracy;Tumour-to-mediastinum ratio;

Secondary

MeasureTime frame
Positive predicative value;Negative predictive value;

Countries

China

Contacts

Public ContactHua Pang

The First Affiliated Hospital of Chongqing Medical University

phua1973@163.com+86 23 8901 2386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 19, 2026